Key result
Trivalent inactivated polio vaccine has become the sole source of protective immunity against type 2 poliovirus in routine immunization programs following the switch to bivalent oral polio vaccine.
Answers are grounded in this paper and cite their sources.
Highlights the transition to inactivated polio vaccine as the sole source of protective immunity against type 2 poliovirus following the withdrawal of trivalent oral polio vaccine.
With the globally coordinated switch from the trivalent oral polio vaccine (OPV) to the bivalent OPV in April, 2016, the international public health community entered a new chapter in the endgame of polio. Although OPV has served as the cornerstone of polio eradication efforts over the past 30 years, trivalent inactivated polio vaccine (IPV) has re-ascended to prominence in the past year, now acting as the sole source of protective immunity against type 2 poliovirus in routine immunisation programmes.
No takes yet. Share an insight, caveat, or question.
Brickley et al. (2017) conducted a review in Polio. Inactivated polio vaccine (IPV) vs. Oral polio vaccine (OPV) was evaluated. Trivalent inactivated polio vaccine has become the sole source of protective immunity against type 2 poliovirus in routine immunization programs following the switch to bivalent oral polio vaccine.
Synapse has enriched 10 related papers. Consider them for comparative context: